Meta-analysis of 15 studies (4,324 premenopausal women with HR+ breast cancer): 3-monthly vs monthly GnRH agonist gave similar ovarian escape (pooled 10%; RR 0.86, 95% CI 0.60–1.22), estradiol levels, DFS, PFS and safety.
Meta-analysisn = 4,324
de Liz et al. Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis